X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Piramal Healthcare with Aventis Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PIRAMAL ENTERPRISES vs SANOFI INDIA - Comparison Results

PIRAMAL ENTERPRISES    Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

SANOFI INDIA 
   Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PIRAMAL ENTERPRISES SANOFI INDIA PIRAMAL ENTERPRISES/
SANOFI INDIA
 
P/E (TTM) x 10.4 39.9 26.1% View Chart
P/BV x 1.8 8.6 20.8% View Chart
Dividend Yield % 0.9 1.0 86.8%  

Financials

 PIRAMAL ENTERPRISES   SANOFI INDIA
EQUITY SHARE DATA
    PIRAMAL ENTERPRISES
Mar-18
SANOFI INDIA
Dec-16
PIRAMAL ENTERPRISES/
SANOFI INDIA
5-Yr Chart
Click to enlarge
High Rs3,0834,560 67.6%   
Low Rs1,9024,400 43.2%   
Sales per share (Unadj.) Rs589.71,028.5 57.3%  
Earnings per share (Unadj.) Rs284.0129.0 220.2%  
Cash flow per share (Unadj.) Rs310.5186.0 167.0%  
Dividends per share (Unadj.) Rs25.0068.00 36.8%  
Dividend yield (eoy) %1.01.5 66.1%  
Book value per share (Unadj.) Rs1,467.0753.6 194.7%  
Shares outstanding (eoy) m180.2723.03 782.8%   
Bonus/Rights/Conversions IS--  
Price / Sales ratio x4.24.4 97.0%   
Avg P/E ratio x8.834.7 25.3%  
P/CF ratio (eoy) x8.024.1 33.3%  
Price / Book Value ratio x1.75.9 28.6%  
Dividend payout %8.852.7 16.7%   
Avg Mkt Cap Rs m449,332103,174 435.5%   
No. of employees `0006.83.6 188.9%   
Total wages/salary Rs m19,8813,592 553.5%   
Avg. sales/employee Rs Th15,535.66,537.7 237.6%   
Avg. wages/employee Rs Th2,905.4991.4 293.0%   
Avg. net profit/employee Rs Th7,482.5819.8 912.8%   
INCOME DATA
Net Sales Rs m106,31023,686 448.8%  
Other income Rs m2,595708 366.6%   
Total revenues Rs m108,90624,394 446.4%   
Gross profit Rs m51,5995,281 977.1%  
Depreciation Rs m4,7731,313 363.5%   
Interest Rs m29,78315 198,553.3%   
Profit before tax Rs m19,6384,661 421.3%   
Minority Interest Rs m2,8010-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-28,7641,691 -1,701.0%   
Profit after tax Rs m51,2032,970 1,724.0%  
Gross profit margin %48.522.3 217.7%  
Effective tax rate %-146.536.3 -403.7%   
Net profit margin %48.212.5 384.1%  
BALANCE SHEET DATA
Current assets Rs m118,15415,673 753.9%   
Current liabilities Rs m462,2606,678 6,922.1%   
Net working cap to sales %-323.738.0 -852.3%  
Current ratio x0.32.3 10.9%  
Inventory Days Days2776 35.0%  
Debtors Days Days4722 208.6%  
Net fixed assets Rs m113,7278,098 1,404.4%   
Share capital Rs m361230 156.5%   
"Free" reserves Rs m264,09317,088 1,545.5%   
Net worth Rs m264,45417,356 1,523.7%   
Long term debt Rs m242,2060-   
Total assets Rs m726,83425,400 2,861.6%  
Interest coverage x1.7311.7 0.5%   
Debt to equity ratio x0.90-  
Sales to assets ratio x0.10.9 15.7%   
Return on assets %11.111.8 94.8%  
Return on equity %19.417.1 113.1%  
Return on capital %10.326.9 38.3%  
Exports to sales %024.5 0.0%   
Imports to sales %028.0 0.0%   
Exports (fob) Rs mNA5,801 0.0%   
Imports (cif) Rs mNA6,627 0.0%   
Fx inflow Rs m15,1107,145 211.5%   
Fx outflow Rs m4,2986,846 62.8%   
Net fx Rs m10,813299 3,616.2%   
CASH FLOW
From Operations Rs m-159,6663,226 -4,949.3%  
From Investments Rs m-17,677-1,555 1,136.8%  
From Financial Activity Rs m186,503-1,818 -10,258.7%  
Net Cashflow Rs m9,364-147 -6,370.3%  

Share Holding

Indian Promoters % 52.9 0.0 -  
Foreign collaborators % 0.0 60.4 -  
Indian inst/Mut Fund % 4.0 14.4 27.8%  
FIIs % 26.6 14.6 182.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 16.5 10.5 157.1%  
Shareholders   93,274 15,184 614.3%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PIRAMAL ENTERPRISES With:   J.B.CHEMICALS  SUVEN LIFE  CIPLA  CADILA HEALTHCARE  ALEMBIC LTD  

Compare PIRAMAL ENTERPRISES With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps Over 275 Points; Realty and Banking Stocks Witness Selling(Closing)

After trading on a volatile note throughout the day, share markets in India witnessed selling pressure during the closing hours and ended the day in red.

Related Views on News

PIRAMAL ENTERPRISES Announces Quarterly Results (1QFY19); Net Profit Down 152.5% (Quarterly Result Update)

Aug 1, 2018 | Updated on Aug 1, 2018

For the quarter ended June 2018, PIRAMAL ENTERPRISES has posted a net profit of Rs 1 bn (down 152.5% YoY). Sales on the other hand came in at Rs 29 bn (up 28.8% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

SANOFI INDIA Announces Quarterly Results (1QFY19); Net Profit Up 35.1% (Quarterly Result Update)

Jul 27, 2018 | Updated on Jul 27, 2018

For the quarter ended June 2018, SANOFI INDIA has posted a net profit of Rs 996 m (up 35.1% YoY). Sales on the other hand came in at Rs 7 bn (up 13.8% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Is It the Right Time to Buy Pharma Stocks Now?(The 5 Minute Wrapup)

Sep 12, 2018

Is the pharma sector poised for a comeback? Is the worst over? I believe so.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PIRAMAL ENTERPRISES SHARE PRICE


Sep 21, 2018 (Close)

TRACK PIRAMAL ENTERPRISES

  • Track your investment in PIRAMAL ENTERPRISES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PIRAMAL ENTERPRISES

PIRAMAL ENTERPRISES 5-YR ANALYSIS

COMPARE PIRAMAL ENTERPRISES WITH

MARKET STATS